S&P 500   2,712.81 (+2.01%)
DOW   23,116.61 (+2.04%)
QQQ   198.63 (+1.13%)
AAPL   263.72 (+1.65%)
FB   172.32 (+2.07%)
MSFT   164.19 (+0.51%)
GOOGL   1,198.21 (+1.32%)
AMZN   2,024.58 (+0.65%)
CGC   14.74 (+1.73%)
NVDA   264.25 (+2.23%)
BABA   194.34 (-1.85%)
MU   47.96 (+3.05%)
TSLA   544.26 (-0.22%)
AMD   48.48 (+1.93%)
ACB   0.84 (+3.73%)
F   4.99 (+5.95%)
NFLX   371.61 (-0.18%)
BAC   22.93 (+3.57%)
GILD   73.87 (-1.07%)
DIS   100.04 (-1.19%)
S&P 500   2,712.81 (+2.01%)
DOW   23,116.61 (+2.04%)
QQQ   198.63 (+1.13%)
AAPL   263.72 (+1.65%)
FB   172.32 (+2.07%)
MSFT   164.19 (+0.51%)
GOOGL   1,198.21 (+1.32%)
AMZN   2,024.58 (+0.65%)
CGC   14.74 (+1.73%)
NVDA   264.25 (+2.23%)
BABA   194.34 (-1.85%)
MU   47.96 (+3.05%)
TSLA   544.26 (-0.22%)
AMD   48.48 (+1.93%)
ACB   0.84 (+3.73%)
F   4.99 (+5.95%)
NFLX   371.61 (-0.18%)
BAC   22.93 (+3.57%)
GILD   73.87 (-1.07%)
DIS   100.04 (-1.19%)
S&P 500   2,712.81 (+2.01%)
DOW   23,116.61 (+2.04%)
QQQ   198.63 (+1.13%)
AAPL   263.72 (+1.65%)
FB   172.32 (+2.07%)
MSFT   164.19 (+0.51%)
GOOGL   1,198.21 (+1.32%)
AMZN   2,024.58 (+0.65%)
CGC   14.74 (+1.73%)
NVDA   264.25 (+2.23%)
BABA   194.34 (-1.85%)
MU   47.96 (+3.05%)
TSLA   544.26 (-0.22%)
AMD   48.48 (+1.93%)
ACB   0.84 (+3.73%)
F   4.99 (+5.95%)
NFLX   371.61 (-0.18%)
BAC   22.93 (+3.57%)
GILD   73.87 (-1.07%)
DIS   100.04 (-1.19%)
S&P 500   2,712.81 (+2.01%)
DOW   23,116.61 (+2.04%)
QQQ   198.63 (+1.13%)
AAPL   263.72 (+1.65%)
FB   172.32 (+2.07%)
MSFT   164.19 (+0.51%)
GOOGL   1,198.21 (+1.32%)
AMZN   2,024.58 (+0.65%)
CGC   14.74 (+1.73%)
NVDA   264.25 (+2.23%)
BABA   194.34 (-1.85%)
MU   47.96 (+3.05%)
TSLA   544.26 (-0.22%)
AMD   48.48 (+1.93%)
ACB   0.84 (+3.73%)
F   4.99 (+5.95%)
NFLX   371.61 (-0.18%)
BAC   22.93 (+3.57%)
GILD   73.87 (-1.07%)
DIS   100.04 (-1.19%)
Log in

NASDAQ:LGNDLigand Pharmaceuticals Stock Price, Forecast & News

$81.54
+3.31 (+4.23 %)
(As of 04/8/2020 01:44 PM ET)
Add
Compare
Today's Range
$78.47
Now: $81.54
$84.93
50-Day Range
$63.37
MA: $86.76
$107.88
52-Week Range
$57.24
Now: $81.54
$130.50
Volume25,791 shs
Average Volume529,946 shs
Market Capitalization$1.35 billion
P/E Ratio2.78
Dividend YieldN/A
Beta1.4
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Read More
Ligand Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.95 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:LGND
CUSIP53220K50
Phone858-550-7500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$120.28 million
Cash Flow$6.66 per share
Book Value$43.68 per share

Profitability

Net Income$629.30 million

Miscellaneous

Employees116
Market Cap$1.35 billion
Next Earnings Date5/6/2020 (Confirmed)
OptionableOptionable

Receive LGND News and Ratings via Email

Sign-up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.


Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions

How has Ligand Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Ligand Pharmaceuticals' stock was trading at $91.83 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, LGND shares have decreased by 11.2% and is now trading at $81.54. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ligand Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ligand Pharmaceuticals.

When is Ligand Pharmaceuticals' next earnings date?

Ligand Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for Ligand Pharmaceuticals.

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) released its earnings results on Thursday, February, 6th. The biotechnology company reported $0.71 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.64 by $0.07. The biotechnology company earned $27 million during the quarter, compared to the consensus estimate of $25.30 million. Ligand Pharmaceuticals had a return on equity of 4.34% and a net margin of 523.19%. The firm's quarterly revenue was down 54.7% compared to the same quarter last year. During the same period last year, the firm earned $1.70 earnings per share. View Ligand Pharmaceuticals' earnings history.

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 27th. The company provided earnings per share guidance of 3.62-3.62 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.47. The company issued revenue guidance of $133-133 million, compared to the consensus revenue estimate of $125.82 million.

What price target have analysts set for LGND?

6 analysts have issued 1-year price objectives for Ligand Pharmaceuticals' shares. Their forecasts range from $132.00 to $229.00. On average, they expect Ligand Pharmaceuticals' stock price to reach $163.20 in the next year. This suggests a possible upside of 100.1% from the stock's current price. View analysts' price targets for Ligand Pharmaceuticals.

What are Wall Street analysts saying about Ligand Pharmaceuticals stock?

Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Ligand reported encouraging second-quarter results with earnings and sales beating estimates. The company’s Captisol Formulation technology resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Ligand is acquiring other technology platforms like OmniAb platform from OMT acquisition to reduce dependence on Captisol formulation. OmniAb is likely to drive future revenues. However, Shares of Ligand have underperformed the industry so far this year. Moreover, Ligand derives a substantial portion of its revenues from royalties associated with the sales of Kyprolis. Any setback to Kyprolis will have an unfavorable impact on the top line. Moreover, increase in inactive licensing deals related to Ligand’s technology platform raises concerns." (8/8/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $214 price target. Our target is based on sum of the parts including: (1) a clinical NPV model of assets in Phase 2 development or greater (currently 30 out of over 200 assets under development); and (2) NPV of current revenues based on our projections for royalties, material sales, and collaborative revenue." (5/3/2019)

Has Ligand Pharmaceuticals been receiving favorable news coverage?

Media stories about LGND stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Ligand Pharmaceuticals earned a news impact score of -3.3 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutLigand Pharmaceuticals.

Are investors shorting Ligand Pharmaceuticals?

Ligand Pharmaceuticals saw a increase in short interest in March. As of March 13th, there was short interest totaling 8,904,900 shares, an increase of 12.6% from the February 27th total of 7,910,000 shares. Based on an average daily volume of 632,600 shares, the short-interest ratio is presently 14.1 days. Currently, 56.1% of the shares of the stock are short sold. View Ligand Pharmaceuticals' Current Options Chain.

Who are some of Ligand Pharmaceuticals' key competitors?

What other stocks do shareholders of Ligand Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Illumina (ILMN), Netflix (NFLX), Intel (INTC), AbbVie (ABBV), Cisco Systems (CSCO) and Gilead Sciences (GILD).

Who are Ligand Pharmaceuticals' key executives?

Ligand Pharmaceuticals' management team includes the following people:
  • Mr. John L. Higgins, CEO & Exec. Director (Age 49)
  • Mr. Matthew W. Foehr, Pres & COO (Age 46)
  • Mr. Matthew Korenberg, Exec. VP of Fin. & CFO (Age 44)
  • Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 50)
  • Mr. Todd Pettingill, Director of Corp. Devel.

What is Ligand Pharmaceuticals' stock symbol?

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Who are Ligand Pharmaceuticals' major shareholders?

Ligand Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Woodstock Corp (0.43%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Sunil Patel and Todd C Davis. View institutional ownership trends for Ligand Pharmaceuticals.

Which institutional investors are selling Ligand Pharmaceuticals stock?

LGND stock was sold by a variety of institutional investors in the last quarter, including Woodstock Corp. View insider buying and selling activity for Ligand Pharmaceuticals.

How do I buy shares of Ligand Pharmaceuticals?

Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ligand Pharmaceuticals' stock price today?

One share of LGND stock can currently be purchased for approximately $81.54.

How big of a company is Ligand Pharmaceuticals?

Ligand Pharmaceuticals has a market capitalization of $1.35 billion and generates $120.28 million in revenue each year. The biotechnology company earns $629.30 million in net income (profit) each year or $2.11 on an earnings per share basis. Ligand Pharmaceuticals employs 116 workers across the globe. View additional information about Ligand Pharmaceuticals.

What is Ligand Pharmaceuticals' official website?

The official website for Ligand Pharmaceuticals is http://www.ligand.com/.

How can I contact Ligand Pharmaceuticals?

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]

This page was last updated on 4/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel